SCHEMBL4383060

SCHEMBL4383060

N#Cc1cc(CON=C2CCN(S(=O)(=O)c3ccc(NC(=O)C(F)(F)F)cc3)CC2)ccc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 3/20 0.41
TP53 P04637 2/20 0.39
ABCC9 O60706 4/20 0.39
ABCC8 Q09428 4/20 0.39
KCNJ11 Q14654 4/20 0.39
KCNJ8 Q15842 4/20 0.39
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
PDK1 Q15118 2/20 0.38
PDK2 Q15119 2/20 0.38
PDK3 Q15120 2/20 0.38
PDK4 Q16654 2/20 0.38
ALDH1A1 P00352 5/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 4/20 0.38
USP2 O75604 2/20 0.38
TSHR P16473 2/20 0.38
LMNA P02545 1/20 0.38
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4382701 0.90 PKM (0.47) MEN1KMT2AALDH1A1SMN1; SMN2GAA
SCHEMBL4381060 0.87 TP53 (0.37) NAMPTTP53MEN1KMT2AALDH1A1
SCHEMBL4385346 0.85 MEN1 (0.43) MEN1KMT2ASMN1; SMN2GAA
SCHEMBL4383813 0.85 RORC (0.43) MEN1KMT2AALDH1A1SMN1; SMN2MAPT
SCHEMBL4385274 0.83 PKM (0.41) MEN1KMT2AALDH1A1SMN1; SMN2GAA
SCHEMBL4380375 0.77 CCR6 (0.45) ALDH1A1SMN1; SMN2KDM4E
SCHEMBL13589008 0.77 KMT2A (0.42) KMT2AALDH1A1SMN1; SMN2MAPTKDM4E
SCHEMBL4383772 0.77 ATM (0.42) ALDH1A1SMN1; SMN2GAAMAPTLMNA
SCHEMBL4381306 0.77 TEK (0.42) TP53MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL4384476 0.76 ALDH1A1 (0.47) MEN1KMT2AALDH1A1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
EP-2040698-A2 OXIME COMPOUNDS AND THE USE THEREOF SHIONOGI & CO., LTD. (JP) 2009-04-01 EP disclosed
WO-2008008398-A2 OXIME COMPOUNDS AND THE USE THEREOF SHIONOGI & CO., LTD. (JP) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF KCNN4, CACNA1A, KCNN3 NAMPT 4023/4885TP53 4415/4885ABCC9 725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.